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Abstract
Purpose—To determine whether associations between estrogen pathway-related single 
nucleotide polymorphisms (SNPs) and breast cancer risk differ by molecular subtype, we 
evaluated associations between SNPs in cytochrome P450 family 19 subfamily A polypeptide 1 
(CYP19A1), estrogen receptor (ESR1), 3-beta hydroxysteroid dehydrogenase type I (HSD3B1), 17-
beta hydroxysteroid dehydrogenase type II (HSD17B2), progesterone receptor (PGR), and sex 
hormone-binding globulin (SHBG) and breast cancer risk in a case-control study in North 
Carolina.
Methods—Cases (N=1,972) were women 20–74 years old and diagnosed with breast cancer 
between 1993 and 2001. Population-based controls (N=1,776) were frequency-matched to cases 
by age and race. 195 SNPs were genotyped and linkage disequilibrium was evaluated using the r2 
statistic. Odds ratios (ORs) and 95% confidence intervals (CIs) for associations with breast cancer 
overall and by molecular subtype were estimated using logistic regression. Monte Carlo methods 
were used to control for multiple comparisons; two-sided P values <3.3 × 10−4 were statistically 
significant. Heterogeneity tests comparing the two most common subtypes, luminal A (N=679) 
and basal-like (N=200), were based on the Wald statistic.
Results—ESR1 rs6914211 (AA vs. AT+TT, OR=2.24, CI: 1.51, 3.33), ESR1 rs985191 (CC vs. 
AA, OR=2.11, CI: 1.43, 3.13), and PGR rs1824128 (TT+GT vs. GG, OR=1.33, CI: 1.14, 1.55) 
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were associated with risk after accounting for multiple comparisons. Rs6914211 and rs985191 
were in strong linkage disequilibrium among controls (African Americans r2=0.70; whites 
r2=0.95). There was no evidence of heterogeneity between luminal A and basal-like subtypes, and 
the three SNPs were also associated with elevated risk of the less common luminal B, HER2+/ER
− and unclassified subtypes.
Conclusions—ESR1 and PGR SNPs were associated with risk, but lack of heterogeneity 
between subtypes suggests variants in hormone-related genes may play similar roles in the 
etiology of breast cancer molecular subtypes.
Keywords
breast cancer; single nucleotide polymorphisms; estrogen receptor; progesterone receptor; 
cytochrome P450 family 19 subfamily A polypeptide 1; 17-beta hydroxysteroid dehydrogenase 
type II; sex hormone-binding globulin; 3-beta hydroxysteroid dehydrogenase type I
Introduction
Breast cancer can be classified into molecular subtypes that differ with respect to biology, 
survival, and some risk factors [1–6]. Although more than 70 single nucleotide 
polymorphisms (SNPs) have been associated with breast cancer risk [7, 8], there have been 
few investigations of genetic variation and risk of specific breast tumor molecular subtypes. 
A pooled analysis examined 10 risk loci and demonstrated heterogeneity of risk associations 
by subtype [9]. More recently, the Carolina Breast Cancer Study (CBCS) demonstrated that 
subtype associations for 78 SNPs in several susceptibility pathways varied by tumor subtype 
[10]. Beyond these two studies, information regarding the heterogeneity of association 
between genetic variants and risk of breast cancer subtypes is limited. Greater understanding 
of the relationship between genetic polymorphisms and specific tumor types may provide 
clues regarding which biological mechanisms are involved in the tumorigenesis of different 
subtypes.
Estrogen and progesterone-related genes are likely candidates for harboring breast cancer 
risk variants due to the central role that estrogen and progesterone play in normal breast 
development and breast cancer [11–13], and may provide clues as to how the estrogen 
pathway functions in tumors. Estrogen bound to the estrogen receptor (ER), encoded by 
ESR1, can act as a transcription factor for genes associated with cell proliferation and 
survival, including growth factors, tumor suppressors, and pro-apoptotic genes [14]. 
Progesterone signaling via the progesterone receptor (PR), encoded by PGR, also influences 
transcription and can act through multiple pathways to stimulate proliferation [15, 16].
Previous analyses of the relationship between non-genetic risk factors and breast cancer 
subtypes in the CBCS indicate that there may be etiologic heterogeneity between breast 
cancer subtypes[4]. Millikan et al. [4] previously reported that associations for some 
reproductive risk factors were qualitatively different between luminal A breast cancers, 
which are defined in part by ER and/or PR expression, and basal-like breast cancers, which 
are defined in part by lack of ER and PR expression. Specifically, parity (vs. nulliparity) was 
inversely associated with luminal A breast cancer regardless of breastfeeding status, whereas 
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parity in women who breastfed was unassociated with the basal-like subtype and parity in 
women who did not breastfeed was positively associated with basal-like breast cancer [4]. 
Additionally, earlier age at first birth was associated with a lower risk of luminal A but 
increased risk of basal-like breast cancer [4]. The fact that these differences were observed 
among reproductive risk factors suggests that this heterogeneity may have a hormonal link.
We hypothesized that hormonal factors related to parity and lactation might influence 
pathways leading to luminal A and basal-like breast cancer in different ways, and that some 
of these differences may be rooted in genetic variation. Therefore, we examined associations 
between SNPs in six genes related to the production, bioavailability, and signaling of 
estrogen and progesterone and breast cancer risk. In addition to ESR1 and PGR, we 
examined genes for cytochrome P450 family 19 subfamily A polypeptide 1 (CYP19A1), 
which converts androgens to estrogens [17]; 17-beta hydroxysteroid dehydrogenase type II 
(HSD17B2), which oxidizes active sex steroids into inactive precursors, including 
conversion of estradiol into estrone [18]; sex hormone-binding globulin (SHBG), which 
binds estrogen in the blood controlling its availability to bind to ER [19, 20]; and 3-beta 
hydroxysteroid dehydrogenase type I (HSD3B1), which converts pregnolone to progesterone 
[17, 21]. Associations were estimated for breast cancer risk overall, and for breast cancer 
molecular subtypes. This investigation was informed by previous findings of non-genetic 
risk factor heterogeneity between luminal A and basal-like subtypes [4], therefore we 




The CBCS is a population-based case-control study of breast cancer in North Carolina, and 
has been described previously [22, 23]. Briefly, eligible cases included women 20 to 74 
years old who were diagnosed with primary invasive breast cancer from 1993 to 2001 and 
lived within the 24-county study area at diagnosis. Women diagnosed with breast carcinoma 
in situ (CIS) were also enrolled from 1996–2001. Cases were identified through the North 
Carolina Central Cancer Registry using rapid case ascertainment. Randomized recruitment 
was used to oversample invasive cases that were African American or < 50 years old [24]. 
Eligible controls included women 20 to 74 years old who lived within the study area and had 
no personal history of breast cancer. Controls were identified through Department of Motor 
Vehicles (< 65 years old) or Health Care Financing Administration (≥ 65 years old) records, 
and were frequency-matched to cases by race and five-year age groups. Case and control 
response rates were 76% and 55% with respect to invasive case recruitment, and 83% and 
65% for CIS recruitment.
A total of 2,311 cases and 2,022 controls provided informed consent and were interviewed 
about breast cancer risk factors, including reproductive and menstrual history, exogenous 
hormone use, and family history of cancer. 2,045 (88%) cases and 1,818 (90%) controls also 
provided a blood sample. DNA was extracted from blood and stored at −80°C. This study 
was approved by the University of North Carolina at Chapel Hill Institutional Review 
Board.
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Breast tumor molecular subtype was determined by immunohistochemical analysis of ER, 
PR, epidermal growth factor receptor (EGFR), c-erb B2/neu (HER2) and cytokeratin 5/6 
(CK 5/6), using methods described previously [4, 25–28]. Tumor tissue was available for 
1,845 of 2,311 cases and immunohistochemistry was completed for 1,424. Cases where 
molecular subtype was determined were more likely to be African American and have later 
stage at diagnosis than cases where subtype data were incomplete, but did not differ by other 
characteristics [4]. Tumors were classified as luminal A (ER+ and/or PR+, HER2−); basal-
like (ER−, PR−, HER2−, CK5/6+ and/or EGFR+); luminal B (ER+ and/or PR+, HER2+); 
HER2+/ER− (ER−, PR−, HER2+); and unclassified (ER−, PR−, HER2−, CK5/6−, EGFR−).
SNP Selection
Tag SNPs for ESR1, HSD3B1, HSD17B2, PGR and SHBG were selected from International 
HapMap Project CEU (European) and YRI (West African) population data [29] using 
Haploview Tagger software [30–32]; data from the HapMap African American population 
was unavailable at the time of SNP selection. A minimum pairwise r2 of 0.80 was used to 
define tags within the genomic regions specified in Table 1. Selection was restricted to SNPs 
with a minimum minor allele frequency of 0.10. SNPs selected from each population were 
combined into a single list. CYP19A1 SNPs were selected from a published list of linkage 
disequilibrium (LD) block tag SNPs in African-American and white women [33, 34]. We 
also included 14 SNPs, identified through a literature search, which had been investigated 
previously for an association with breast cancer risk or a functional effect (Table 1). In total, 
207 SNPs were selected for study.
Genotyping
SNPs were genotyped at the University of North Carolina Mammalian Genotyping Core 
using the Illumina GoldenGate assay (Illumina, Inc., San Diego, CA) as part of a 1,536-SNP 
panel. Panel results and quality control measures were reported in detail previously [35]. 
Exact tests for deviation from Hardy-Weinberg equilibrium were conducted among controls, 
stratified by self-identified race [36]. Genotyping cluster images were re-reviewed for SNPs 
with Hardy-Weinberg test P-values < 0.01; all SNPs reviewed during this process had good 
signal intensity and none were excluded. 195 of the 207 (94%) selected SNPs had acceptable 
data and were included in this analysis (Table 1). Additionally, ancestry informative markers 
(AIMs) specifically selected to maximize the differences between African and European 
ancestral populations based on differences in allele frequencies and Fisher’s information 
content were genotyped for each participant [35, 37]. 144 of 158 AIMs passed quality 
control and were used in the analysis.
2,039 cases and 1,818 controls had DNA available for genotyping. Subjects were excluded 
from analysis if there were genotype calls for < 95% of SNPs (N=103), genotype-
determined sex was male (N=5), or there was suspected contamination (N=1), resulting in 
data for 1,972 cases and 1,776 controls (Online Resource 1). Subjects without genotype data 
were more likely to be cases, recruited after 1996, or African American, but did not differ by 
other risk factors or molecular subtype (among cases). 1,220 cases had both genotype and 
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molecular subtype data (luminal A, N=679; basal-like, N=200, luminal B, N=116; 
HER2+/ER−, N=94; unclassified, N=131).
Covariates
Age was defined as age in years at breast cancer diagnosis (cases) or recruitment (controls). 
Self-identified race was reported during the study interview. Less than 2% of participants 
were Native American/Eskimo, Asian/Pacific Islander, Hispanic, or mixed race, and were 
grouped with white women as non-African American. Self-identified race was missing for 
two participants, who were excluded from analysis. Proportion of African or European 
ancestry was estimated from 144 AIMs using maximum likelihood estimation, based on the 
observed allele frequencies in the study population, the contributions from the ancestral 
populations, and the differences in allele frequency between the ancestral populations [37–
39]. Methods assumed two ancestral populations (European and African), such that the 
proportion of African ancestry was equal to 1 minus the proportion of European ancestry. 
Estimates of African ancestry were included in regression models as a proportion ranging 
from 0 to 0.96 (the maximum observed value).
Statistical Analysis
Genotype frequencies for each SNP were calculated stratified by self-identified race and 
adjusted for the sampling probabilities used to select participants. LD between SNPs was 
estimated by calculating pairwise r2 in Haploview according to self-identified race and case 
status [30]. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association 
between genotypes and overall breast cancer risk were estimated using unconditional binary 
logistic regression in SAS v9.1 (SAS, Cary, NC). Subtype-specific associations were 
estimated using unconditional polytomous logistic regression. Genotype associations were 
modeled using the general statistical model (2 degrees of freedom). If the number of 
participants homozygous for the rare allele was less than five cases, less than five controls, 
or less than 10 cases and 10 controls, the rare homozygote and heterozygote groups were 
combined. Furthermore, if the results indicated that the underlying genetic model was 
recessive, dominant, or additive, additional analyses specific to that model were conducted. 
The Wald test was used to evaluate heterogeneity of basal-like and luminal A regression 
coefficients from the polytomous logistic regression model. The null hypothesis was that the 
coefficients were equal for the two subtypes. Additionally, we conducted exploratory 
analyses examining associations with luminal B, HER2+/ER−, and unclassified subtypes 
and estimating race-stratified subtype associations. In order to evaluate the effect of 
including CIS cases in the analysis, we re-evaluated associations excluding CIS study 
participants.
All statistical tests were two-sided. Monte Carlo methods were used to approximate the joint 
distribution of test statistics and evaluate the family-wise error rate to control for multiple 
comparisons, insuring that correlation among SNPs did not result in an overly conservative 
correction [40]. The nominal alpha level indicating statistical significance for genotype 
associations was 0.05; the Monte Carlo-adjusted level was 3.3 × 10−4.
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All models were adjusted for the frequency-matching factors (age and self-identified race) 
and the proportion of African ancestry in order to control for residual population 
stratification. Models also included an offset term in order to account for the randomized 
recruitment case-sampling strategy and to produce population-based effect estimates [24, 
41].
Results
Of 195 SNPs genotyped (Online Resource 2, Online Resource 3), ESR1 rs6914211 (AA vs. 
AT+TT OR=2.24, 95% CI: 1.51–3.33), ESR1 rs985191 (CC vs. AA OR=2.11, 95% CI: 
1.43–3.13), and PGR rs1824128 (GT+TT vs. GG OR=1.33, 95% CI: 1.14–1.55) were 
positively associated with overall breast cancer risk after accounting for multiple 
comparisons (Table 2). Associations between rs6914211 and rs985191 and the luminal A 
and basal-like subtypes were similar to associations with breast cancer overall and were not 
statistically different from each other (heterogeneity test: rs6914211 P=0.58; rs985191 
P=0.57), though associations with basal-like breast cancer were not statistically significant. 
SNPs rs6914211 and rs985191 are approximately 15 Kb apart on chromosome 6, and were 
in strong LD in the CBCS (African American: controls r2=0.70, cases r2=0.76; white: 
controls r2=0.95, cases r2=0.96). Rs6914211 and rs985191 were also moderately correlated 
with a third ESR1 SNP, rs9397463, among whites but not African Americans (Online 
Resource 4). Rs9397463 was positively associated with risk of all subtypes of breast cancer, 
but the association was statistically significant only for risk of luminal B tumors (Online 
Resource 3).
Associations between rs1824128 and the luminal A and basal-like subtypes were weaker 
than the association with breast cancer overall and there was no evidence of heterogeneity 
between the subtypes (P=0.80; Table 2). Rs1824128 was in strong LD with PGR 
rs11224575 among all subjects, and in moderate LD with PGR rs11224579 among white 
cases and controls (Online Resource 4); rs11224575 and rs11224579 were positively, but 
not significantly, associated with breast cancer risk (Online Resource 3). All associations 
remained similar after the exclusion of CIS study participants (data not shown).
To determine whether the rs6914211, rs985191, and rs1824128 associations were consistent 
across other tumor types, we examined their associations with HER2+/ER−, luminal B, and 
unclassified subtypes. The direction of association was consistent with what was seen for 
breast cancer overall, with the exception that rs1824128 was not associated with the luminal 
B subtype (Online Resource 5). Associations between rs6914211 and rs985191 and luminal 
B breast cancer were particularly strong. For each, two copies of the risk allele was 
associated with an approximately 5-fold increase in luminal B risk (rs6914211 AA vs. AT
+TT OR=4.96, 95% CI: 2.37–10.38; rs985191 CC vs. AA OR=5.12, 95% CI: 2.41–10.86). 
With the exception of the previously mentioned luminal B associations with rs6914211, 
rs985191, and rs9397463, no other SNPs were significantly associated with luminal B, 
HER2+/ER−, or unclassified tumors after accounting for multiple comparisons. When we 
explored whether subtype-specific associations for these SNPs differed by self-identified 
race, we found that the association between PGR rs1824128 and risk was stronger among 
African Americans than non-African Americans for all subtypes except the unclassified 
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tumors. However, these associations were imprecise due to the small number of cases in 
some subgroups (Online resource 6).
No suspected functional SNPs met our Monte Carlo-adjusted criteria for an association with 
risk; however, CYP19A1 rs700519 was associated with a reduced risk of breast cancer 
overall at the nominal significance level of 0.05 (TT vs. CC OR=0.44, 95% CI: 0.21–0.89; 
Table 3). An inverse association was also noted for luminal A and basal-like subtype, 
although the luminal A association was slightly weaker than the overall association.
Discussion
We investigated the association between SNPs in CYP19A1, ESR1, HSD3B1, HSD17B2, 
PGR and SHBG and breast cancer risk and identified two SNPs in ESR1 and one in PGR 
that were associated with breast cancer risk. There was no association between HSD3B1, 
HSD17B2 or SHBG variants and risk. Statistical significance criteria were adjusted for the 
effective number of comparisons made, but it is still possible that some of the significant 
associations we observed were due to chance.
An increasing number of studies have evaluated heterogeneity of SNP associations by tumor 
characteristics, including ER, PR, and HER2 and other clinical characteristics [42–49], but 
few have considered intrinsic molecular subtype, which defines basal-like breast cancer as a 
specific type of ER-negative breast cancer. Studies that have evaluated molecular subtypes 
have shown that genetic associations [9, 10] and gene expression levels [50] differ by 
molecular subtype for some risk alleles. Although variants in estrogen and progesterone 
signaling pathway-related genes have been investigated previously for associations with 
overall breast cancer risk, we examined associations between these variants and luminal A 
and basal-like breast cancer subtypes because subtype differences in hormonally-related 
non-genetic risk factors and differences in ER and PR expression suggested that genetic 
risks related to hormonal pathways may differ between these subtypes as well. However, in 
this study associations for genetic variants in estrogen and progesterone pathway genes were 
largely similar for the luminal A and basal-like subtypes. Although case numbers were 
small, positive associations for rs6914211, rs985191, and rs1824128 were generally 
consistent for luminal B, HER2+/ER−, and unclassified tumors as well.
ESR1 rs6914211 and rs985191 were associated with breast cancer risk in this study. 
Previously, in a large pooled analysis, rs985191 was found to be positively but not 
significantly associated with breast cancer risk [51]; to our knowledge no previous studies 
have identified rs6914211 as having an association with risk. Rs6914211 and rs985191 are 
located close to other risk-associated regions on chromosome 6. ESR1 rs3020314 and ESR1 
rs3020401 were identified as potentially associated with risk in a two-stage candidate SNP 
analysis [52] and rs3020314 was associated with ER-positive breast cancer in a three-stage 
study of ESR1 tag SNPs [51]. Rs3020314 and rs3020401 were in low to moderate LD with 
rs6914211 and rs985191 among white CBCS participants (r2 ranging from 0.28 to 0.32). In 
this study, rs3020401 was positively associated with risk of all subtypes except for 
HER2+/ER−, but at levels below our criteria accounting for multiple comparisons, whereas 
rs3020314 was not associated with overall or subtype-specific risk. It is possible that 
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rs3020314/rs3020401 and rs6914211/rs985191 are reflecting associations related to the 
same causal locus and inconsistencies between studies may be a result of regional variation 
in LD between study populations. Fine-mapping of this region may help illuminate the 
nature of the causal locus (or loci) that may be near these SNPs.
In addition to these tag SNP associations, genome wide association studies (GWAS) have 
also identified breast cancer risk loci on 6q25.1: one within ESR1 [46] and two > 60 KB 
upstream of ESR1 [53, 54]. The upstream SNPs are in close proximity to C6ORF97 and 
C6ORF211, genes of unknown function whose expression is highly correlated with ESR1 
expression [55]. These GWAS risk variants were not genotyped in this analysis; however, 
future investigations of 6q25.1 should consider joint analyses of regions within and 
upstream of ESR1, as the co-expression profiles suggest a biological relationship.
PGR intronic SNP rs1824128 was also associated with breast cancer risk. To our 
knowledge, previous studies have not identified rs1824128 as associated with risk nor has 
11q22.1 been identified as a harboring risk loci in breast cancer GWAS. Much of the 
investigation into PGR variants and breast cancer risk has focused on the functional 
polymorphism +331 G/A (rs10895068), which was not associated with risk in this study or a 
recent meta-analysis [56]. Thus, replication of the rs1824128 association is necessary before 
the meaning of this association can be assessed.
Our analysis of potentially functional SNPs suggested an inverse association between the 
CYP19A1 rs700519 (R264C) TT genotype and risk of breast cancer overall. Although this 
association did not meet the multiple comparison-adjusted criteria for statistical significance, 
there is prior evidence that the R264C change may be associated with risk. Some have 
reported that 264C results in reduced hydrophobicity, reduced CYP19A1 expression, and 
lower aromatase activity [57, 58]; lower aromatase activity would be consistent with the 
association between the TT genotype and lower breast cancer risk in the CBCS. However, 
another study reported no difference in enzymatic activity between 264R and 264C [59] and 
rs700519 was not associated with risk in other epidemiologic studies [33, 60, 61]. The 
rs700519 TT genotype is uncommon, and was rare in CBCS non-African American 
participants. A lack of association with breast cancer risk in previous studies may be 
explained by the low prevalence of the at-risk genotype in populations of non-African 
descent.
Molecular subtype data was not available for all enrolled cases; however, genotype 
distributions only differed between cases with and without molecular subtype data for four 
SNPs (HSD17B2 rs3111351 and rs8191136 in African Americans, and ESR1 rs6557177 and 
rs985695 in non-African Americans). This is within the number expected to differ due to 
chance alone, suggesting that results were likely not biased due to the inability to include all 
cases in subtype-specific analyses. Other limitations of this analysis included low SNP 
density in some genes and limited statistical power for identifying subtype heterogeneity. 
The SNP selection method we employed selected SNPs based on LD with other SNPs (i.e., 
tag SNPs), such that a single SNP may be a marker for other correlated SNPs. This tagging 
method has been shown to provide efficient coverage of gene regions [32], however failure 
of tag SNPs during genotyping may have led to low coverage in some areas. The number of 
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basal-like cases was relatively low in comparison to the number of luminal A cases, and 
heterogeneity tests may have lacked power. However, visual comparison of ORs for the 3 
SNPs most strongly associated with overall risk show similar associations luminal A and 
basal-like subtypes with the same direction of effect; thus it is unlikely that any meaningful 
heterogeneity was overlooked for these particular SNPs.
The major strength of this analysis was the ability to examine molecular subtypes in a large, 
population-based study. These IHC-determined subtypes have unique risk factor profiles and 
are related to breast cancer prognosis [4, 5, 25], but the contribution of genetic susceptibility 
to the risk of each subtype has not yet been determined. Our ability to detect statistical 
differences between luminal A and basal-like associations was limited, but our results show 
clear positive associations between the 3 risk SNPs and basal-like and luminal A breast 
cancers, as well as luminal B, HER2+/ER−, and unclassified subtypes. These data suggest 
that genetic variants in pathways primarily related to hormonal mechanisms may be 
important factors for ER-negative as well as ER-positive subtypes. We can only speculate as 
to why differences in association by molecular subtype were not observed. One possible 
explanation is that heterogeneity may be related to polymorphisms in hormonally-related 
genes not evaluated in this study. We evaluated six genes, but there are several other 
hormonally-related candidate genes that may be differentially related to risk of breast cancer 
subtypes. Another possibility is that the non-genetic risk factor heterogeneity observed may 
be related aspects of parity and lactation that are not directly related to sex hormones. 
Further investigation of the relationship between hormonal and non-hormonal biomarkers 
and risk of breast cancer subtypes is needed to understand the relative contributions of each 
biological pathway.
Another strength was that African American participants were oversampled, providing an 
opportunity for exploratory analyses of molecular subtype risk stratified by self-identified 
race. Despite recent efforts to conduct large-scale studies of genetic variation and breast 
cancer risk in African Americans, most early genetic susceptibility studies have consisted 
primarily of women of European descent. We explored associations stratified by self-
identified race with the hypothesis that there may be risk-associated variants that are more 
prevalent in African or African-American populations. This may include variants associated 
with risk of basal-like breast cancer, a subtype that is more prevalent among African 
Americans [4]. Furthermore, because LD range can differ between populations of African as 
compared with European descent [63, 64], it is possible that a tag SNP may have different 
levels of correlation with causal loci in different populations. Thus, a SNP may be 
associated with risk among subjects with one genetic background and weakly or not 
associated among subjects with another. In this population, CYP19A1 R264C was more 
prevalent among African Americans and associations with PGR rs1824128 were stronger 
among African Americans, an observation that was largely consistent across subtypes but 
was based on small numbers and must be interpreted with caution.
Genotype frequencies for rs1824128 were similar comparing African American and non-
African American participants, and so differing prevalence of the risk allele is not a fitting 
explanation for why the rs1824128 association might be limited to African Americans. As 
mentioned previously, there is no data pointing to any functional effect associated with 
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rs1824128 and the association requires replication in order to be confirmed. It is possible 
that the observed differences by race were due to chance. In an analysis of GWAS-identified 
and candidate gene SNPs, O’Brien and colleagues [10] found that molecular subtype-
specific associations differed between African Americans and non-African Americans for a 
minority of SNPs they examined; however, that study was also carried out within the CBCS 
and was subject to the same power limitations that we experienced in this study. Future 
analyses intended to focus primarily on racial differences in risk of breast cancer subtypes 
will require even larger case numbers, and would be most efficiently carried out through 
pooled analyses. Finally, all statistical models were adjusted for the proportion of African 
ancestry, controlling for potential confounding due to population stratification.
In conclusion, this analysis identified genetic variants in ESR1, PGR and CYP19A1 that 
were associated with breast cancer risk and there was little evidence of heterogeneity 
between luminal A and basal-like subtypes. Associations in ESR1 and CYP19A1 were 
consistent with data from other studies. Further characterization of the effects of these SNPs 
or related loci on gene expression could increase our understanding of the biological 
pathways active in breast carcinogenesis.
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